Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Atu027

Known as: Anti-PKN3 siRNA Atu027 
A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RNA, Small Interfering

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Correction to: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market
The published article contains an error in Figure 5. The term “Atu027” should be substituted by “Patisiran” in figure and legend. 
  • figure 5
2016
2016
A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.
385 Background: Atu027 is a liposomally formulated short interfering RNA with anti-metastatic activity, which silences expression… Expand
Highly Cited
2014
Highly Cited
2014
First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.
PURPOSE Atu027 is a novel liposomal RNA interference therapeutic that includes a short-interfering RNA (siRNA), which silences… Expand
2014
2014
siRNA nanoparticles: the future of RNAi therapeutics for oncology?
siRNA clinical trials: state of the art With the emergence of siRNA-based nanomedicine as a powerful therapeutic strategy for… Expand
2013
2013
First-in-human phase I study of the liposomal RNAi therapeutic Atu027 in patients with advanced cancer.
2508 Background: Atu027 is a novel vascular stabilising, anti-metastatic, RNAi therapeutic, targeting systemic endothelial cell… Expand
Highly Cited
2012
Highly Cited
2012
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.
Chemically synthesized, small interfering RNAs (siRNA) are currently used as a new class of therapeutic molecules, allowing the… Expand
2012
2012
Antimetastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumors.
e13597 Background: Atu027 contains siRNA-lipoplexes, which elicits RNAi mediated suppression on PKN3 in vascular endothelial… Expand
2011
2011
First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors.
3057 Background: Atu027 is a novel RNAi therapeutic based on cationic lipoplexes containing chemically stabilized siRNAs, which… Expand
Highly Cited
2010
Highly Cited
2010
Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models
Purpose: Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Highly Cited
2008
Highly Cited
2008
Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression.
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE